268 related articles for article (PubMed ID: 21082942)
1. Use of defibrotide in the treatment and prevention of veno-occlusive disease.
Richardson P; Linden E; Revta C; Ho V
Expert Rev Hematol; 2009 Aug; 2(4):365-76. PubMed ID: 21082942
[TBL] [Abstract][Full Text] [Related]
2. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
3. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
Ho VT; Linden E; Revta C; Richardson PG
Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
[TBL] [Abstract][Full Text] [Related]
4. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
5. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
6. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Ho VT; Revta C; Richardson PG
Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
[TBL] [Abstract][Full Text] [Related]
7. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide.
Corbacioglu S; Hönig M; Lahr G; Stöhr S; Berry G; Friedrich W; Schulz AS
Bone Marrow Transplant; 2006 Oct; 38(8):547-53. PubMed ID: 16953210
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
10. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
12. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
Shah MS; Jeevangi NK; Joshi A; Khattry N
J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.
Corbacioglu S; Greil J; Peters C; Wulffraat N; Laws HJ; Dilloo D; Straham B; Gross-Wieltsch U; Sykora KW; Ridolfi-Lüthy A; Basu O; Gruhn B; Güngör T; Mihatsch W; Schulz AS
Bone Marrow Transplant; 2004 Jan; 33(2):189-95. PubMed ID: 14661036
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
[TBL] [Abstract][Full Text] [Related]
15. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
16. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
Kayikci O; Akpinar S; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease.
Dignan F; Gujral D; Ethell M; Evans S; Treleaven J; Morgan G; Potter M
Bone Marrow Transplant; 2007 Jul; 40(1):79-82. PubMed ID: 17502897
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of defibrotide.
Richardson PG; Corbacioglu S; Ho VT; Kernan NA; Lehmann L; Maguire C; Maglio M; Hoyle M; Sardella M; Giralt S; Holler E; Carreras E; Niederwieser D; Soiffer R
Expert Opin Drug Saf; 2013 Jan; 12(1):123-36. PubMed ID: 23228043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
